Bill Text: TX HB4288 | 2023-2024 | 88th Legislature | Introduced

Texas House Bill 4288

Introduced

Bill Title: Relating to a study on the use of alternative therapies for treating post-traumatic stress disorder.

Spectrum: Partisan Bill (Democrat 1-0)

Status: (Introduced - Dead) 2023-03-21 - Referred to Public Health [HB4288 Detail]

Download: Texas-2023-HB4288-Introduced.html

	88R11662 LRM-F

	By: Raymond	H.B. No. 4288



	A BILL TO BE ENTITLED
	AN ACT
	relating to a study on the use of alternative therapies for treating
	post-traumatic stress disorder.
	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
	SECTION 1. Sections 1(b), (c), (d), and (f), Chapter 983
	(H.B. 1802), Acts of the 87th Legislature, Regular Session, 2021,
	are amended to read as follows:
	(b) The commission, in collaboration with Baylor College of
	Medicine and in partnership with a military veterans hospital, [or]
	a medical center that provides medical care to veterans, or a
	facility licensed in this state that provides Ketamine-related
	mental health services, shall conduct a study on the efficacy of
	using alternative therapies, including the use of
	3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and
	ketamine, in the treatment of veterans and other identified
	individuals who suffer from post-traumatic stress disorder.
	(c) In conducting the study described by Subsection (b) of
	this section, the commission in collaboration with the Baylor
	College of Medicine shall:
	(1) perform a clinical trial on the therapeutic
	efficacy of using psilocybin in the treatment of
	treatment-resistant post-traumatic stress disorder in veterans and
	other identified individuals; [~~and~~]
	(2) prescribe standardized protocols for each
	researcher or research organization participating in the study; and
	(3) review current literature regarding:
	(A) the safety and efficacy of
	3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and
	ketamine in the treatment of post-traumatic stress disorder; and
	(B) the access veterans and other identified
	individuals have to 3,4-methylenedioxymethamphetamine (MDMA),
	psilocybin, and ketamine for treatment of post-traumatic stress
	disorder in the United States.
	(d) The commission shall prepare and submit to the governor,
	the lieutenant governor, the speaker of the house of
	representatives, and each member of the legislature:
	(1) quarterly reports on the progress of the study
	conducted under this section; and
	(2) not later than December 1, 2026 [~~2024~~], a written
	report containing the results of the study conducted under this
	section and any recommendations for legislative or other action.
	(f) This Act expires September 1, 2027 [~~2025~~].
	SECTION 2. This Act takes effect immediately if it receives
	a vote of two-thirds of all the members elected to each house, as
	provided by Section 39, Article III, Texas Constitution. If this
	Act does not receive the vote necessary for immediate effect, this
	Act takes effect September 1, 2023.